In this article, we are going to take a look at where Gilead Sciences, Inc. (NASDAQ:GILD) stands against the other pharma dividend stocks. The pharmaceutical industry in 2024 faced a relatively ...

its phase III HIV drug trial reduced new infections by 96% when compared to background HIV incidence, which could be a game changer for the disease.” Gilead Sciences, Inc. (NASDAQ:GILD ...

Gilead's stock has surged due to successful launches of Livdelzi for PBC and promising developments in lenacapavir for HIV prevention. Livdelzi's approval and strong market potential, combined ...

Gilead (GILD) and Terray Therapeutics announced that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

-- Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest -- FOSTER CITY, Calif. & LOS ANGELES--(BUSINESS WIRE ...

Gilead (GILD) Sciences announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion recommending seladelpar for the treatment of ...

-- Gilead and Terray Will Leverage Terray’s tNova Drug Discovery Platform to Identify Small Molecule Therapeutics Against Targets of Interest -- -- Gilead Has Exclusive Option to Develop and ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule ...

Ending the HIV epidemic is closer than ever, yet disparities persist. Global decision makers must prioritise equitable care to ensure all people can reach the best health outcomes possible.